CBLL logo

CeriBell Inc. (CBLL)

$25.97

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on CBLL

Market cap

$1.01B

EPS

-1.93

P/E ratio

--

Price to sales

8.89

Dividend yield

--

Beta

0.859015

Price on CBLL

Previous close

$26.42

Today's open

$26.39

Day's range

$25.91 - $26.82

52 week range

$12.65 - $28.89

Profile about CBLL

CEO

Xingjuan Chao

Employees

327

Headquarters

Sunnyvale, CA

Exchange

Nasdaq Global Select

Shares outstanding

38835010

Issue type

Common Stock

CBLL industries and sectors

Healthcare

Medical Equipment & Supplies

News on CBLL

CeriBell Q3 Earnings Call Highlights

CeriBell NASDAQ: CBLL reported third-quarter revenue growth of approximately 30% as the company added a record number of hospital accounts and increased usage of its seizure-monitoring platform among existing customers. Management also outlined plans to commercially launch its Delirium Monitoring Solution and introduce its next-generation Omni hardware platform in 2027.

news source

MarketBeat • Nov 4, 2026

news preview

CeriBell, Inc. (CBLL) Q3 2026 Earnings Call Transcript

CeriBell, Inc. (CBLL) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 4, 2026

news preview

Ceribell Reports Third Quarter 2026 Financial Results

SUNNYVALE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the third quarter ended September 30, 2026.

news source

GlobeNewsWire • Nov 3, 2026

news preview

Compared to Estimates, CeriBell, Inc. (CBLL) Q3 Earnings: A Look at Key Metrics

The headline numbers for CeriBell, Inc. (CBLL) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

news source

Zacks Investment Research • Nov 4, 2026

news preview

CeriBell, Inc. (CBLL) Reports Q3 Loss, Tops Revenue Estimates

CeriBell, Inc. (CBLL) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.37 per share a year ago.

news source

Zacks Investment Research • Nov 4, 2026

news preview

Ceribell Expands Its Point-of-Care Brain Monitoring Platform with Commercial Launch of Delirium Monitoring Solution

SUNNYVALE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Ceribell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the commercial launch of its delirium monitoring solution on its point-of-care brain monitoring platform.

news source

GlobeNewsWire • Nov 2, 2026

news preview

Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

SUNNYVALE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Scott Blumberg, CFO, will participate in a fireside chat at the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York City. The fireside chat will take place on Wednesday, November 11, 2026, at 7:00 a.m. Pacific Standard Time / 10:00 a.m. Eastern Standard Time.

news source

GlobeNewsWire • Oct 28, 2026

news preview

Ceribell to Report Third Quarter 2026 Financial Results on November 3, 2026

SUNNYVALE, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the third quarter of 2026 after the close of trading on Tuesday, November 3, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on November 3, 2026.

news source

GlobeNewsWire • Oct 20, 2026

news preview

Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis

SUNNYVALE, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has cleared new software for the Ceribell System that makes it easier and faster for clinicians to interpret longitudinal brain activity and make appropriate clinical decisions.1 Brain monitoring with electroencephalography (EEG) can generate hours of complex data that can be difficult to interpret in a timely manner.

news source

GlobeNewsWire • Sep 30, 2026

news preview

CeriBell Expands EEG Platform Beyond Seizures With Delirium, Pediatric Push

CeriBell NASDAQ: CBLL outlined its plans to expand its brainwave-monitoring platform beyond seizure detection, pointing to new products for delirium, pediatric patients and eventually stroke as it continues to build its hospital customer base.

news source

MarketBeat • Aug 12, 2026

news preview

¹ Disclosures

Get started with M1

Invest in CeriBell Inc.

Open an M1 investment account to buy and sell CeriBell Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in CBLL on M1